Cost of treatment for multidrug-resistant tuberculosis in South Korea

Respirology

Volumn 11, Issue 6, 2006, Pages 793-798

  Kang, Young Ae ^a   Choi, Yong Jun ^b   Cho, Young Jae ^a   Lee, Sang Min ^a   Yoo, Chul Gyu ^a   Kim, Young Whan ^a   Han, Sung Koo ^a   Shim, Young Soo ^a   Yim, Jae Joon ^a  

^a Seoul National University   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Cost; Multidrug resistant; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DOSE TIME EFFECT RELATION; DRUG SENSITIVITY; FATALITY; FEMALE; HEALTH CARE COST; HUMAN; MALE; MORTALITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PRODUCTIVITY; PROGNOSIS; SOUTH KOREA; SURGICAL TECHNIQUE; TUBERCULOSIS;

ADULT; EFFICIENCY, ORGANIZATIONAL; FEMALE; HEALTH CARE COSTS; HUMANS; KOREA; MALE; MIDDLE AGED; PREVALENCE; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 33750057967     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.00948.x     Document Type: Article

References (25)

1. World Health Organization. WHO Report 2005; Global Tuberculosis Control. Surveillance, Planning, Financing 2005. Available from URL: http://www.who.int/ tb/en (accessed 24 May 2006).
2. Broekmans JF, Migliori GB, Rieder HL et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur. Respir. J. 2002; 19: 765-75.
3. Dye C, Espinal MA, Watt CJ et al. Worldwide incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 2002; 185: 1197-202.
4. Iseman MD. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med. 1993; 329: 784-91.
5. Espinal MA, Kim SJ, Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-45.
6. Schluger NW. The impact of drug resistance on the global tuberculosis epidemic. Int. J. Tuberc. Lung Dis. 2000; 4: S71-5.
7. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung. Dis. 2004; 8: 1012-16.
8. Korean National Statistical Office. The consumer price index. Available from URL: http://kosis.nso.go.kr (accessed 24 May 2006).
9. Korean Institute for Health and Social Affairs. National Health and Nutrition Survey. Available from URL: http://www.kihasa.re.kr (accessed 24 May 2006).
10. Korean Ministry of Labor. The Basic Statistical Survey of Wage Structure. Available from URL: http://molab.go.kr (accessed 24 May 2006).
11. Korean Academy of Asthma, Allergy and Clinical Immunology. Social Cost of Asthma. 2005.
12. Kamolratanakul P, Sawert H, Kongsin S et al. Economic impact of tuberculosis at the household level. Int. J. Tuberc. Lung Dis. 1999; 3: 596-602.
13. Gandy M. Science, society, and disease: emerging perspectives. Curr. Opin. Pulm. Med. 2001; 7: 170-2.
14. Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ 2002; 325: 1282-6.
15. White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000; 55: 962-3.
16. Kamolratanakul P, Hiransuthikul N, Singhadong N et al. Cost analysis of different types of tuberculosis patient at tuberculosis centers in Thailand. Southeast Asian J. Trop. Med. Public Health 2002; 33: 321-30.
17. Kizkin O, Hacievliyagil SS, Turker G et al. The cost of treatment in new case and multidrug resistant case in pulmonary tuberculosis. Tuberk Toraks 2003; 51: 410-15.
18. World Health Organization. DOTS-PLUS and the Green Light Committee Available from URL: http://www.who.int/tb/dots/dotsplus/management/en (accessed 24 May 2006).
19. Gupta R, Kim JY, Espinal MA et al. Public health. Responding to market failures in tuberculosis control. Science 2001; 293: 1049-51.
20. Kim HJ, Kang CH, Kim YT et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur. Respir. J. 2006;[Epub ahead of print].
21. Chiang CY, Yu MC, Bai KJ et al. Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. Int. J. Tuberc. Lung Dis. 2001; 5: 272-7.
22. Pomerantz BJ, Cleveland JC Jr, Olson HK et al. Pulmonary resection for multi-drug resistant tuberculosis. J. Thorac. Cardiovasc. Surg. 2001; 121: 448-53.
23. Chan ED, Laurel V, Strand MJ et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2004; 169: 1103-9.
24. Shiraishi Y, Nakajima Y, Katsuragi N et al. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis. J. Thorac. Cardiovasc. Surg. 2004; 128: 523-8.
25. World Health Organization. The Stop TB Initiative 2000 series. Economic Impact of Tuberculosis. Available from URL: http://www.stoptb.org/ stop_tb_initiative/amsterdam_conference/documents/ahlburg.pdf (accessed 24 May 2006).